import { Helmet } from "@/compat/react-helmet-async";
import { Link } from "@/compat/react-router-dom";
import Navigation from "@/components/Navigation";
import Footer from "@/components/Footer";
import { Button } from "@/components/ui/button";
import { Card } from "@/components/ui/card";
import { getBlogPostMeta } from "@/utils/getBlogPostMeta";
import { Activity, TrendingDown, Heart } from "lucide-react";
import { TopicClusterNav } from "@/components/blog/TopicClusterNav";
import { getClusterNavigation } from "@/utils/relatedContent";

const TirzepatideCholesterol = () => {
  const postMeta = getBlogPostMeta("tirzepatide-cholesterol");
  const publishDate = postMeta?.date || "2025-04-16";
  const readTime = postMeta?.readTime || "14 min";
  const clusterNav = getClusterNavigation("tirzepatide-cholesterol");
  
  return (
    <>
      <Helmet>
        <title>Tirzepatide and Cholesterol: Lipid Profile Improvements Explained | Trimi</title>
        <meta name="description" content="How tirzepatide improves cholesterol levels and reduces cardiovascular risk. Evidence-based guide to lipid profile benefits from Mounjaro and Zepbound treatment." />
        <meta name="keywords" content="tirzepatide cholesterol, mounjaro lipids, zepbound triglycerides, tirzepatide LDL, cardiovascular benefits" />
        <meta name="author" content="Dr. Michael Chen, MD, Endocrinology" />
        
        
        <meta property="og:title" content="Tirzepatide and Cholesterol: Lipid Profile Improvements" />
        <meta property="og:description" content="Clinical evidence on how tirzepatide improves cholesterol and reduces cardiovascular disease risk." />
        <meta property="og:type" content="article" />
        <meta property="og:url" content="https://trytrimi.com/blog/tirzepatide-cholesterol" />
        <meta property="article:published_time" content={publishDate} />
        <meta property="article:author" content="Dr. Michael Chen" />
        
        <script type="application/ld+json">
          {JSON.stringify({
            "@context": "https://schema.org",
            "@type": "MedicalWebPage",
            "headline": "Tirzepatide and Cholesterol: Lipid Profile Improvements Explained",
            "datePublished": publishDate,
            "author": {
              "@type": "Person",
              "name": "Dr. Michael Chen",
              "jobTitle": "Endocrinologist"
            }
          })}
        </script>
      </Helmet>
      
      <Navigation />
      <main className="min-h-screen bg-gradient-to-b from-background to-secondary/20">
        <article className="container mx-auto px-4 py-12 max-w-4xl">
          <Link to="/blog" className="text-primary hover:underline mb-6 inline-block">
            ← Back to Blog
          </Link>
          
          <header className="mb-8">
            <h1 className="text-4xl md:text-5xl font-bold mb-4 text-foreground">
              Tirzepatide and Cholesterol: How It Improves Your Lipid Profile
            </h1>
            <div className="flex flex-wrap items-center gap-4 text-muted-foreground mb-6">
              <time dateTime={publishDate}>
                {new Date(publishDate).toLocaleDateString('en-US', { 
                  year: 'numeric', 
                  month: 'long', 
                  day: 'numeric' 
                })}
              </time>
              <span>•</span>
              <span>{readTime} read</span>
              <span>•</span>
              <span>By Dr. Michael Chen, MD</span>
            </div>
          </header>

          <div className="prose prose-lg max-w-none">
            <p className="text-xl leading-relaxed text-muted-foreground mb-8">
              Beyond impressive weight loss results, tirzepatide demonstrates significant improvements in cholesterol and triglyceride levels. Clinical trials show consistent reductions in LDL ("bad") cholesterol, dramatic decreases in triglycerides, and modest improvements in HDL ("good") cholesterol—all contributing to reduced cardiovascular disease risk.
            </p>

            <Card className="p-6 my-8 bg-primary/5 border-primary/20">
              <div className="flex items-start gap-4">
                <Heart className="w-8 h-8 text-primary flex-shrink-0 mt-1" />
                <div>
                  <h3 className="text-lg font-semibold mb-2 text-foreground">Remarkable Finding</h3>
                  <p className="text-muted-foreground">
                    In the SURMOUNT-1 trial, patients on the highest tirzepatide dose (13.5mg) experienced triglyceride reductions of up to 30% along with meaningful improvements in all lipid parameters—changes that translate into significant cardiovascular protection.<sup>1</sup>
                  </p>
                </div>
              </div>
            </Card>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Understanding Cholesterol and Cardiovascular Risk</h2>
            
            <p>
              Before exploring tirzepatide's effects, it's essential to understand what cholesterol numbers mean for your health:
            </p>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">The Lipid Panel Components</h3>

            <div className="bg-secondary/30 p-6 rounded-lg my-6">
              <ul className="space-y-4">
                <li>
                  <strong className="text-foreground">Total Cholesterol:</strong>
                  <p className="text-muted-foreground mt-1">Overall cholesterol in your blood; optimal is under 200 mg/dL</p>
                </li>
                <li>
                  <strong className="text-foreground">LDL Cholesterol ("Bad"):</strong>
                  <p className="text-muted-foreground mt-1">Deposits in arteries causing plaque buildup; optimal is under 100 mg/dL</p>
                </li>
                <li>
                  <strong className="text-foreground">HDL Cholesterol ("Good"):</strong>
                  <p className="text-muted-foreground mt-1">Removes LDL from arteries; optimal is above 60 mg/dL</p>
                </li>
                <li>
                  <strong className="text-foreground">Triglycerides:</strong>
                  <p className="text-muted-foreground mt-1">Fat in blood that increases heart disease risk; optimal is under 150 mg/dL</p>
                </li>
                <li>
                  <strong className="text-foreground">Non-HDL Cholesterol:</strong>
                  <p className="text-muted-foreground mt-1">Total cholesterol minus HDL; captures all "bad" cholesterol types; optimal is under 130 mg/dL</p>
                </li>
              </ul>
            </div>

            <p>
              High LDL cholesterol and triglycerides contribute to atherosclerosis—the buildup of fatty deposits in arteries that leads to heart attacks and strokes. Every 39 mg/dL reduction in LDL cholesterol reduces cardiovascular events by approximately 22%.<sup>2</sup>
            </p>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Clinical Evidence: Tirzepatide's Effects on Lipids</h2>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">SURMOUNT Clinical Trial Program</h3>

            <p>
              The SURMOUNT trials (Tirzepatide Once Weekly for the Treatment of Obesity) provided comprehensive data on lipid improvements:
            </p>

            <div className="bg-secondary/30 p-6 rounded-lg my-6">
              <h4 className="font-semibold mb-4 text-foreground">SURMOUNT-1 Lipid Results (72 weeks)</h4>
              
              <div className="space-y-4">
                <div>
                  <p className="font-medium text-foreground">5mg Dose:</p>
                  <ul className="mt-2 space-y-1 text-muted-foreground">
                    <li>• Triglycerides: -15.3% decrease</li>
                    <li>• LDL cholesterol: -6.2% decrease</li>
                    <li>• Total cholesterol: -7.8% decrease</li>
                    <li>• HDL cholesterol: +5.8% increase</li>
                  </ul>
                </div>

                <div>
                  <p className="font-medium text-foreground">10mg Dose:</p>
                  <ul className="mt-2 space-y-1 text-muted-foreground">
                    <li>• Triglycerides: -23.4% decrease</li>
                    <li>• LDL cholesterol: -8.7% decrease</li>
                    <li>• Total cholesterol: -9.9% decrease</li>
                    <li>• HDL cholesterol: +7.1% increase</li>
                  </ul>
                </div>

                <div>
                  <p className="font-medium text-foreground">15mg Dose:</p>
                  <ul className="mt-2 space-y-1 text-muted-foreground">
                    <li>• Triglycerides: -29.8% decrease</li>
                    <li>• LDL cholesterol: -10.4% decrease</li>
                    <li>• Total cholesterol: -11.2% decrease</li>
                    <li>• HDL cholesterol: +8.6% increase<sup>1</sup></li>
                  </ul>
                </div>
              </div>
            </div>

            <Card className="p-6 my-8 bg-accent/10 border-accent/30">
              <div className="flex items-start gap-4">
                <TrendingDown className="w-8 h-8 text-accent flex-shrink-0 mt-1" />
                <div>
                  <h3 className="text-lg font-semibold mb-2 text-foreground">Dose-Dependent Benefits</h3>
                  <p className="text-muted-foreground">
                    Lipid improvements increase with higher tirzepatide doses, but even the 6mg maintenance dose provides meaningful cardiovascular benefits for most patients.
                  </p>
                </div>
              </div>
            </Card>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">SURMOUNT-2: Diabetes Population</h3>

            <p>
              In patients with type 2 diabetes—who typically have worse lipid profiles—tirzepatide showed even more impressive results:
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>Triglycerides:</strong> Reductions of 15-28% depending on dose</li>
              <li><strong>Non-HDL cholesterol:</strong> Decreased by 10-13%</li>
              <li><strong>ApoB (Apolipoprotein B):</strong> Reduced by 8-12%</li>
              <li><strong>VLDL cholesterol:</strong> Decreased by 18-31%<sup>3</sup></li>
            </ul>

            <p>
              These improvements occurred alongside significant weight loss and improved glycemic control, demonstrating tirzepatide's comprehensive metabolic benefits.
            </p>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">How Tirzepatide Improves Cholesterol</h2>

            <p>
              Tirzepatide enhances lipid profiles through multiple complementary mechanisms:
            </p>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">1. Weight Loss-Mediated Effects</h3>

            <ul className="space-y-3 my-6">
              <li><strong>Reduced hepatic fat production:</strong> Less liver fat means less VLDL and triglyceride synthesis</li>
              <li><strong>Improved insulin sensitivity:</strong> Better insulin action reduces triglyceride production</li>
              <li><strong>Decreased visceral adiposity:</strong> Less inflammatory fat reduces atherogenic lipoproteins</li>
              <li><strong>Enhanced lipoprotein clearance:</strong> Better metabolism of triglyceride-rich particles</li>
            </ul>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">2. Direct Metabolic Effects</h3>

            <p>
              Beyond weight loss, tirzepatide has direct effects on lipid metabolism:<sup>4</sup>
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>GLP-1 receptor activation:</strong> Reduces postprandial lipemia (fat in blood after meals)</li>
              <li><strong>GIP receptor activation:</strong> Improves fatty acid oxidation and energy expenditure</li>
              <li><strong>Reduced inflammation:</strong> Lower inflammatory markers that damage blood vessels</li>
              <li><strong>Improved endothelial function:</strong> Better cholesterol transport and metabolism</li>
              <li><strong>Enhanced lipoprotein lipase activity:</strong> More efficient triglyceride breakdown</li>
            </ul>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Timeline: When to Expect Lipid Improvements</h2>

            <div className="bg-secondary/20 p-6 rounded-lg my-8">
              <h3 className="text-xl font-semibold mb-4 text-foreground">Progressive Lipid Changes Over Time</h3>
              
              <div className="space-y-6">
                <div>
                  <h4 className="font-semibold text-primary mb-2">Months 1-3: Early Response</h4>
                  <p className="text-muted-foreground">
                    Triglycerides typically respond first, with reductions of 5-15% as weight loss begins. LDL changes are modest initially (2-4% decrease).
                  </p>
                </div>

                <div>
                  <h4 className="font-semibold text-primary mb-2">Months 4-6: Accelerating Improvements</h4>
                  <p className="text-muted-foreground">
                    As weight loss progresses (typically 10-15% body weight), lipid improvements accelerate. Triglycerides may drop 15-20%, LDL decreases 5-8%.
                  </p>
                </div>

                <div>
                  <h4 className="font-semibold text-primary mb-2">Months 7-12: Maximum Benefits</h4>
                  <p className="text-muted-foreground">
                    Peak lipid improvements occur around the time of maximum weight loss. Full dose-dependent effects are typically realized by month 9-12.
                  </p>
                </div>

                <div>
                  <h4 className="font-semibold text-primary mb-2">Long-Term Maintenance</h4>
                  <p className="text-muted-foreground">
                    With sustained weight maintenance, lipid improvements persist. Some patients can reduce or discontinue cholesterol medications under medical supervision.
                  </p>
                </div>
              </div>
            </div>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Managing Cholesterol Medications with Tirzepatide</h2>

            <Card className="p-6 my-8 border-destructive/30 bg-destructive/5">
              <h3 className="text-lg font-semibold mb-3 text-foreground flex items-center gap-2">
                <Activity className="w-5 h-5 text-destructive" />
                Important Medical Note
              </h3>
              <p className="text-muted-foreground">
                Never adjust or stop cholesterol medications without consulting your healthcare provider. Many patients with established cardiovascular disease need to continue statins regardless of cholesterol levels due to proven cardiovascular protection.
              </p>
            </Card>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">When Medication Adjustments May Be Appropriate</h3>

            <p>
              Some patients may be candidates for medication reduction if they meet certain criteria:
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>Primary prevention patients:</strong> Those without existing cardiovascular disease</li>
              <li><strong>Achieved optimal lipid levels:</strong> LDL under 70 mg/dL, triglycerides under 150 mg/dL</li>
              <li><strong>Significant weight loss:</strong> 15% or more of body weight</li>
              <li><strong>No other cardiovascular risk factors:</strong> Normal blood pressure, non-smoker</li>
              <li><strong>Previously on medication for borderline values:</strong> Not high-risk patients</li>
            </ul>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Patients Who Should Continue Cholesterol Medications</h3>

            <p>
              These patient groups typically need to maintain cholesterol-lowering therapy:<sup>5</sup>
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>Previous heart attack or stroke:</strong> Statins provide protection beyond cholesterol lowering</li>
              <li><strong>Known coronary artery disease:</strong> Requires ongoing lipid management</li>
              <li><strong>Diabetes with additional risk factors:</strong> High-risk group needing aggressive treatment</li>
              <li><strong>Familial hypercholesterolemia:</strong> Genetic condition requiring lifelong treatment</li>
              <li><strong>Very high baseline LDL:</strong> Above 190 mg/dL typically needs medication</li>
            </ul>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Maximizing Lipid Benefits on Tirzepatide</h2>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Dietary Strategies for Optimal Lipids</h3>

            <ul className="space-y-3 my-6">
              <li><strong>Reduce saturated fat:</strong> Limit to less than 7% of total calories</li>
              <li><strong>Eliminate trans fats:</strong> Avoid partially hydrogenated oils completely</li>
              <li><strong>Increase soluble fiber:</strong> Oats, beans, apples, Brussels sprouts (5-10g daily)</li>
              <li><strong>Add plant sterols:</strong> Fortified foods can reduce LDL by 5-15%</li>
              <li><strong>Choose healthy fats:</strong> Olive oil, avocados, nuts, fatty fish</li>
              <li><strong>Limit refined carbohydrates:</strong> White bread, sugary foods raise triglycerides</li>
            </ul>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Lifestyle Modifications</h3>

            <ul className="space-y-3 my-6">
              <li><strong>Regular aerobic exercise:</strong> 150 minutes weekly raises HDL and lowers triglycerides</li>
              <li><strong>Resistance training:</strong> Improves body composition and insulin sensitivity</li>
              <li><strong>Smoking cessation:</strong> Dramatically improves HDL and vascular health</li>
              <li><strong>Moderate alcohol:</strong> Up to 1 drink daily for women, 2 for men may raise HDL</li>
              <li><strong>Weight maintenance:</strong> Sustaining weight loss maintains lipid improvements</li>
            </ul>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Monitoring Recommendations</h3>

            <ul className="space-y-3 my-6">
              <li><strong>Baseline lipid panel:</strong> Before starting tirzepatide</li>
              <li><strong>3-month follow-up:</strong> Check response after initial weight loss</li>
              <li><strong>6-month assessment:</strong> Evaluate progress and adjust medications if needed</li>
              <li><strong>Annual monitoring:</strong> Once stabilized on treatment</li>
              <li><strong>Advanced testing if indicated:</strong> ApoB, Lp(a), particle size analysis</li>
            </ul>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Special Populations and Considerations</h2>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Patients with Severe Hypertriglyceridemia</h3>

            <p>
              Tirzepatide is particularly beneficial for patients with very high triglycerides (above 500 mg/dL):
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>Pancreatitis prevention:</strong> Reducing triglycerides lowers acute pancreatitis risk</li>
              <li><strong>Dramatic reductions possible:</strong> 30-40% decreases in some patients</li>
              <li><strong>May reduce need for fibrates:</strong> Some patients can discontinue additional medications</li>
              <li><strong>Improves insulin resistance:</strong> Often the underlying cause of high triglycerides</li>
            </ul>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Metabolic Syndrome</h3>

            <p>
              Patients with metabolic syndrome (characterized by abdominal obesity, high blood pressure, elevated triglycerides, low HDL, and insulin resistance) see comprehensive improvements:
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>Addresses multiple components:</strong> Weight, blood pressure, lipids, insulin sensitivity</li>
              <li><strong>Reduces cardiovascular risk:</strong> Metabolic syndrome increases heart disease risk 2-3 fold</li>
              <li><strong>May reverse diagnosis:</strong> Significant improvements can eliminate metabolic syndrome classification</li>
            </ul>

            <h3 className="text-2xl font-semibold mt-8 mb-4 text-foreground">Non-Alcoholic Fatty Liver Disease (NAFLD)</h3>

            <p>
              Tirzepatide shows promising effects on liver health, which impacts lipid metabolism:
            </p>

            <ul className="space-y-3 my-6">
              <li><strong>Reduces hepatic steatosis:</strong> Decreases fat accumulation in liver</li>
              <li><strong>Improves liver enzymes:</strong> ALT and AST levels often normalize</li>
              <li><strong>Decreases VLDL production:</strong> Less triglyceride synthesis by fatty liver</li>
              <li><strong>May prevent progression to NASH:</strong> Reduces inflammation and fibrosis risk<sup>6</sup></li>
            </ul>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">Tirzepatide vs Other Weight Loss Medications for Lipids</h2>

            <p>
              How do tirzepatide's lipid effects compare to other GLP-1 medications?
            </p>

            <div className="bg-secondary/30 p-6 rounded-lg my-6">
              <h4 className="font-semibold mb-3 text-foreground">Comparative Lipid Effects</h4>
              
              <ul className="space-y-4">
                <li>
                  <strong className="text-primary">Tirzepatide (GLP-1/GIP):</strong>
                  <p className="text-muted-foreground mt-1">Triglycerides -15-30%, LDL -6-10%, HDL +5-9%</p>
                </li>
                <li>
                  <strong className="text-primary">Semaglutide (GLP-1):</strong>
                  <p className="text-muted-foreground mt-1">Triglycerides -12-18%, LDL -3-5%, HDL +2-4%</p>
                </li>
                <li>
                  <strong className="text-primary">Liraglutide (GLP-1):</strong>
                  <p className="text-muted-foreground mt-1">Triglycerides -8-12%, LDL -2-4%, HDL +2-3%</p>
                </li>
              </ul>

              <p className="text-muted-foreground mt-4">
                <em>Tirzepatide's dual GLP-1/GIP mechanism appears to provide superior triglyceride reduction compared to GLP-1-only medications, though all show cardiovascular benefits.</em>
              </p>
            </div>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">The Bottom Line on Tirzepatide and Cholesterol</h2>

            <p>
              Tirzepatide offers substantial improvements in lipid profiles beyond its impressive weight loss effects. The combination of reduced triglycerides, lower LDL cholesterol, decreased non-HDL cholesterol, and modestly increased HDL creates a favorable cardiovascular risk profile.
            </p>

            <p>
              These lipid improvements are clinically meaningful—the magnitude of change is similar to adding a moderate-intensity statin for many patients. When combined with weight loss, blood pressure reduction, improved insulin sensitivity, and reduced inflammation, tirzepatide provides comprehensive cardiometabolic protection.
            </p>

            <p>
              The key to maximizing lipid benefits is combining tirzepatide treatment with heart-healthy dietary changes, regular exercise, and appropriate medical monitoring. While some patients may be able to reduce cholesterol medications, this decision should always be made in consultation with a healthcare provider based on individual cardiovascular risk.
            </p>

            <div className="bg-primary/10 border-l-4 border-primary p-6 my-8">
              <h3 className="text-xl font-semibold mb-3 text-foreground">Medical Disclaimer</h3>
              <p className="text-sm text-muted-foreground">
                This article is for educational purposes only and does not constitute medical advice. Lipid management requires individualized medical care. Never adjust cholesterol medications without consulting your healthcare provider. Tirzepatide should only be used under medical supervision. Individual lipid responses vary based on baseline values, genetics, diet, and other factors.
              </p>
            </div>

            <h2 className="text-3xl font-bold mt-12 mb-6 text-foreground">References</h2>
            
            <ol className="space-y-2 text-sm text-muted-foreground">
              <li>1. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." <em>New England Journal of Medicine</em>. 2022;387(3):205-216.</li>
              <li>2. Baigent C, et al. "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins." <em>The Lancet</em>. 2005;366(9493):1267-1278.</li>
              <li>3. Garvey WT, et al. "Two-year effects of tirzepatide for the treatment of obesity: SURMOUNT-2 trial." <em>Obesity</em>. 2023;31(8):2025-2040.</li>
              <li>4. Nauck MA, et al. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction." <em>Cardiovascular Diabetology</em>. 2022;21(1):169.</li>
              <li>5. Grundy SM, et al. "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." <em>Circulation</em>. 2019;139(25):e1082-e1143.</li>
              <li>6. Gastaldelli A, et al. "Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial." <em>The Lancet Diabetes & Endocrinology</em>. 2022;10(6):393-406.</li>
            </ol>

            <div className="mt-12 pt-8 border-t border-border">
              <h3 className="text-2xl font-semibold mb-6 text-foreground">Related Articles</h3>
              <div className="grid gap-4">
                <Link to="/blog/tirzepatide-heart-health" className="text-primary hover:underline">
                  → Tirzepatide and Heart Health: Cardiovascular Benefits & Safety
                </Link>
                <Link to="/blog/tirzepatide-weight-loss-results" className="text-primary hover:underline">
                  → Tirzepatide Weight Loss Results: What to Expect Month by Month
                </Link>
                <Link to="/blog/tirzepatide-vs-semaglutide" className="text-primary hover:underline">
                  → Tirzepatide vs Semaglutide: Which Is Right for You?
                </Link>
              </div>
            </div>
          </div>

          <div className="mt-12 text-center">
            <Link to="/treatments">
              <Button size="lg" className="text-lg px-8">
                Explore Tirzepatide Treatment Options
              </Button>
            </Link>
          </div>
        </article>
      </main>
      
      <TopicClusterNav
        pillarPage={clusterNav.pillarPage}
        hubPage={clusterNav.hubPage}
        relatedArticles={clusterNav.relatedInCluster}
        topic="Tirzepatide"
      />

      <Footer />
    </>
  );
};

export default TirzepatideCholesterol;